(NASDAQ: LQDA) Liquidia's forecast annual revenue growth rate of 85.33% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.61%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.34%.
Liquidia's revenue in 2025 is $69,216,000.On average, 10 Wall Street analysts forecast LQDA's revenue for 2025 to be $6,383,902,534, with the lowest LQDA revenue forecast at $4,217,280,029, and the highest LQDA revenue forecast at $10,960,560,903. On average, 10 Wall Street analysts forecast LQDA's revenue for 2026 to be $29,322,697,500, with the lowest LQDA revenue forecast at $11,484,273,711, and the highest LQDA revenue forecast at $55,830,221,170.
In 2027, LQDA is forecast to generate $38,327,599,945 in revenue, with the lowest revenue forecast at $17,946,298,188 and the highest revenue forecast at $57,821,547,776.